SCHEMBL22171996

SCHEMBL22171996

CCN1CCN(c2ccc(NC(C)=O)c(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)c2)CC1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 9/20 0.84
FGFR1 P11362 18/20 0.80
FGFR2 P21802 5/20 0.80
FGFR3 P22607 5/20 0.80
JAK2 O60674 2/20 0.78
ABL1 P00519 2/20 0.78
INSR P06213 2/20 0.78
LCK P06239 2/20 0.78
FYN P06241 2/20 0.78
YES1 P07947 2/20 0.78
LYN P07948 2/20 0.78
RET P07949 2/20 0.78
MET P08581 2/20 0.78
ROS1 P08922 2/20 0.78
KIT P10721 2/20 0.78
SRC P12931 2/20 0.78
BRAF P15056 2/20 0.78
PDGFRA P16234 2/20 0.78
FLT1 P17948 2/20 0.78
TYK2 P29597 2/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2014816 0.93 FGFR1 (0.83) FGFR4FGFR1FGFR2FGFR3JAK2
SCHEMBL2014529 0.92 FGFR1 (0.81) FGFR4FGFR1FGFR2FGFR3JAK2
SCHEMBL16659479 0.92 FGFR4 (1.00) FGFR4FGFR1FGFR2FGFR3
SCHEMBL16654071 0.90 FGFR1 (0.79) FGFR4FGFR1FGFR2FGFR3JAK2
SCHEMBL2012965 0.90 FGFR1 (0.79) FGFR4FGFR1FGFR2FGFR3JAK2
SCHEMBL16665219 0.90 FGFR1 (0.80) FGFR4FGFR1FGFR2FGFR3JAK2
H3B-6527 SCHEMBL29412748 0.89 FGFR1 (1.00) FGFR4FGFR1FGFR2FGFR3
H3B-6527 SCHEMBL30274661 0.89 FGFR1 (1.00) FGFR4FGFR1FGFR2FGFR3
H3B-6527 SCHEMBL16659467 0.89 FGFR1 (1.00) FGFR4FGFR1FGFR2FGFR3
SCHEMBL16655805 0.88 FGFR1 (1.00) FGFR4FGFR1FGFR2FGFR3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10912774-B2 Pyrimidine FGFR4 inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-02-09 US disclosed
US-20200206222-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10912774-B2 Pyrimidine FGFR4 inhibitors FGFR4, FGFR1, FGFR3 FGFR4 1/4885FGFR1 2/4885FGFR2 4/4885
US-20200206222-A1 PYRIMIDINE FGFR4 INHIBITORS FGFR4, FGFR1, FGFR3 FGFR4 1/4885FGFR1 2/4885FGFR2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.